Stem cell therapy seen to reduce itch, pain in RDEB children in trial

Stem cell therapy seen to reduce itch, pain in RDEB children in trial

The stem cell therapy CORDStrom, in the pipeline at Inmune Bio, was found in a clinical trial to reduce itch and pain in children — from infants to teenagers — with intermediate and severe recessive dystrophic epidermolysis bullosa (RDEB), new data show. The treatment candidate also reduced disease activity and skin involvement for the study’s participants, who ranged in age from 6 months to 15 years. These new data, from the MissionEB study (IS…